Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting.

导出 OA

翻译打印收藏纠错

第一作者： Renpei,Kato

第一单位： Department of Urology, Iwate Medical University School of Medicine, Yahaba, Japan. Electronic address: rekato@iwate-med.ac.jp.

作者： Renpei,Kato ^[1] ; Daiki,Ikarashi ^[2] ; Tomohiko,Matsuura ^[2] ; Shigekatsu,Maekawa ^[2] ; Yoichiro,Kato ^[2] ; Mitsugu,Kanehira ^[2] ; Ryo,Takata ^[2] ; Rie,Tokuyama ^[3] ; Kanako,Tamai ^[3] ; Naoto,Harigai ^[3] ; Yukoh,Nakazaki ^[3] ; Wataru,Obara ^[2]

作者单位： Department of Urology, Iwate Medical University School of Medicine, Yahaba, Japan. Electronic address: rekato@iwate-med.ac.jp. ^[1] Department of Urology, Iwate Medical University School of Medicine, Yahaba, Japan. ^[2] Chiome Bioscience Inc., Tokyo, Japan. ^[3]

DOI 10.1016/j.tranon.2020.100771

PMID 32375081

发布时间 2021-01-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览4

Translational oncology

2020年13卷6期

100771页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting.

Translational oncology

相似文献

Translational oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting.

Translational oncology

相似文献

Translational oncology

相关期刊

检索历史清除